Last reviewed · How we verify
NCT05448625
Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)
trial testing Genoss DES in Drug-eluting Stent in 200 participants. Completed in 23 September 2025.
14 May 2025
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 26 May 2022 |
| Primary completion | 14 May 2025 |
| Estimated completion | 23 September 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Genoss DES
Conditions studied
- Drug-eluting Stent — all drugs for Drug-eluting Stent →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Yonsei University
Who can join
19 and older, any sex, with Drug-eluting Stent or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective cohort study to evaluate the long-term effect and safety of Genoss drug-eluting stents (DES) in patients with coronary artery disease with high ischemic features.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases.
Alsaab HO, Alharbi FD, Alhibs AS, Alanazi NB, et al · · 2022 · cited 141× · PMID 36559223 · DOI 10.3390/pharmaceutics14122728
Verify or expand the search:
- PubMed search for NCT05448625
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Genoss DES
Trials testing the same drug.
- NCT03045913 — Genoss DES Prospective Multicenter Registry · completed
Other recruiting trials for Drug-eluting Stent
Currently open trials in the same condition.
- NCT06066450 — Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis · recruiting
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05448625 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05448625.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing